Results 101 to 110 of about 79,407 (254)

[Tenofovir and entecavir for chronic hepatitis B infection treatment: a single-center experience]

Clinical Management Issues, 2015
BACKGROUND AND AIM: The current treatment of chronic hepatitis B infection (CHBV) has achieved several step-ups thanks to the introduction of the new-generation nucleos(t)ide analogs.
Fabio Tarsetti, Giuseppe Tarantino, Piergiorgio Mosca, Emidio Scarpellini, Giammarco Fava   +4 more
doaj   +1 more source

Impact of chronic hepatitis B virus infection on bone mineral density

Medical Journal of Babylon, 2020
Background: Chronic hepatitis B virus (HBV) infection is a common health problem that has a worldwide distribution. Apart from the direct effect of the virus on the liver, there are many extrahepatic manifestations among which the probable effect on bone
Istabraq A Al-Husseiny, Maysaa K Al-Malkey, Maitham A Al-Sammak, Faheema J Abo-Alhur   +3 more
doaj   +1 more source

Ethical Allocation of Preexposure HIV Prophylaxis [PDF]

, 2011
Civil society-led movements transformed global AIDS action from deep skepticism about extending anti-retroviral (ARV) treatment in low and middle-income countries to an historic scaling up of treatment towards universal access.
Gostin, Lawrence O., Kim, Susan C.
core   +1 more source

Ten‐year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection

Liver international (Print), 2019
Tenofovir disoproxil fumarate (TDF) is a first‐line treatment for chronic hepatitis B (CHB). We aimed to describe the efficacy and safety profiles of TDF treatment for up to 10 years in a well‐described cohort of CHB patients.
P. Marcellin, D. Wong, W. Sievert, P. Buggisch, J. Petersen, R. Flisiak, M. Manns, K. Kaita, Z. Krastev, Samuel S. Lee, A. Cathcart, G. Crans, M. L. Op den Brouw, B. Jump, A. Gaggar, J. Flaherty, M. Buti   +16 more
semanticscholar   +1 more source

Exploring the impact of Cabotegravir‐Rilpivirine long‐acting on weight gain, body composition and quality of life in adults living with HIV

HIV Medicine, EarlyView.
Abstract Introduction Long‐acting injectable antiretroviral therapy (ART) with Cabotegravir (CAB) and Rilpivirine (RPV) offers an alternative to daily oral regimens, improving adherence and patient satisfaction. However, its impact on body composition and metabolism remains underexplored.
Andrea De Vito, Andrea Marongiu, Antonella Cano, Mariangela Puci, Agnese Colpani, Susanna Maria Nuvoli, Maria Grazia Catte, Giulia Moi, Maria Antonietta Deledda, Sergio Uzzau, Giovanni Sotgiu, Franca Deriu, Angela Spanu, Giordano Madeddu   +13 more
wiley   +1 more source

Advanced Liver Disease Events in People with HIV and Hepatitis B Virus Coinfection Initiating Antiretroviral Therapy in the United States

Infectious Diseases and Therapy
Introduction HIV/hepatitis B virus (HBV) coinfection elevates the risk of liver-related complications compared to HIV or HBV mono-infections. While some antiretroviral therapy (ART) regimens slow liver disease progression, the long-term effects of ...
Ching-Yi Chuo, Woodie Zachry, Melanie de Boer, Laura Telep, Li Tao   +4 more
doaj   +1 more source

Backbone switch to abacavir/lamivudine fixed-dose combination: implications for antiretroviral therapy optimization [PDF]

, 2015
Current guidelines recommend treatment optimization in virologically suppressed patients through switching/ simplification strategies to minimize long-term toxicities and improve adherence. The assessment of inflammation/ coagulation profiles may support
FALASCA, FRANCESCA, FANTAUZZI, Alessandra, Floridia, Marco, MEZZAROMA, Ivano, SPANEDDA, Pierpaolo, TURRIZIANI, Ombretta, VULLO, Vincenzo   +6 more
core  

An Asymptomatic Lesion on the Penis

JEADV Clinical Practice, EarlyView.
Brandon Tan, Karen Cheung, Xin Liu, Alexis Daniel Lara Rivero   +3 more
wiley   +1 more source

Virological outcomes with Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in people previously treated with darunavir‐based antiretroviral therapy

HIV Medicine, EarlyView.
Abstract Background Darunavir‐based antiretroviral therapy (ART) is commonly used in people with HIV who experience adherence challenges and/or have complex resistance patterns. Changes in ART commissioning have led to an increased use of Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in these populations despite limited real‐world outcome ...
Rhianna Sheridan, Yasmin Osei‐Kuffour Ekert, Lucy Campbell, Mark Zuckerman, Sally Hawkins, Kate Childs, Frank A. Post   +6 more
wiley   +1 more source

Virological outcomes of second-line protease inhibitor-based treatment for human immunodeficiency virus type 1 in a high-prevalence rural South African setting: a competing-risks prospective cohort analysis [PDF]

, 2017
Background. Second-line antiretroviral therapy (ART) based on ritonavir-boosted protease inhibitors (bPIs) represents the only available option after first-line failure for the majority of individuals living with human immunodeficiency virus (HIV ...
2LADY Study Group, Alexandra Calmy, Anne Derache, ANRS 12249 TasP Study Group, Collins Iwuji, Dami Collier, DART Virology Group and Trial Team, Deenan Pillay, EARNEST Trial Team, Francois Dabis, National Department of Health, National Department of Health, Nonhlanhla Okesola, PharmAccess African Studies to Evaluate Resistance (PASER), PharmAccess African Studies to Evaluate Resistance (PASER), Ravindra K. Gupta, SECOND-LINE, SECOND-LINE Study Group, Southern African Treatment and Resistance Network, TenoRes Study Group, Tulio de Oliveira, World Health Organization, World Health Organization   +22 more
core   +3 more sources